NEOS Investment Management LLC Boosts Stock Position in Pfizer Inc. $PFE

NEOS Investment Management LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 48.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 681,017 shares of the biopharmaceutical company’s stock after purchasing an additional 223,163 shares during the quarter. NEOS Investment Management LLC’s holdings in Pfizer were worth $17,352,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Brighton Jones LLC increased its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the period. United Bank increased its holdings in shares of Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after buying an additional 6,415 shares during the last quarter. Signature Estate & Investment Advisors LLC raised its position in shares of Pfizer by 19.3% during the 2nd quarter. Signature Estate & Investment Advisors LLC now owns 22,976 shares of the biopharmaceutical company’s stock valued at $557,000 after buying an additional 3,722 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Pfizer in the second quarter valued at approximately $9,582,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $27.37 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The company has a market cap of $155.62 billion, a P/E ratio of 20.13 and a beta of 0.47. The stock has a 50-day moving average of $25.88 and a two-hundred day moving average of $25.26. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.63 earnings per share. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Morgan Stanley lowered their target price on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. Daiwa Securities Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target for the company. in a research report on Thursday, February 12th. Finally, Scotiabank initiated coverage on shares of Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.00.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.